tubular epithelial antigen and found their incapability in distinguishing cause of injury. [6] Biomarkers of renal damage can be differentiated into markers of renal function and markers of renal injury. CysC a low-molecular-weight protein with a constant rate of production by nucleated cells and is not affected by age gender and muscle mass. It is freely filtered at the glomerulus and completely reabsorbed in the proximal tubule. Its presence in the urine reflects the impairment of protein uptake by the proximal tubules. [7] . It has been observed that s CysC differentiates an abnormal glomerular filtration rate (GFR) more sensitively than SCr in stable transplant patients. [8] . Earlier studies investigated potential biomarkers for the diagnosis of AKI and one among them was KIM. [9, 10] It is a transmembrane protein containing an Ig-like and mucin-like domain. It clears the debris from the damaged renal tubules playing a phagocytic process in activated epithelial renal tubules. [11] It can be excreted in the urine immediately after the ischemic insult and before the regeneration of the epithelium. Urinary KIM-1 has been reported to be a noninvasive, rapid, sensitive, and reproducible biomarker of experimental nephrotoxic and ischemic AKI. It has been noted that urinary interleukin-18 and NGAL correlate well with the graft outcome, but in the immediate transplant period when intervention may not be helpful. [12] Thus, it is very important to identify a biomarker that predicts early graft dysfunction as well as the tubular injury which will help in the graft management and therapeutic interventions. We hypothesized that detecting early signs of rejection may enable early intervention leading to a better outcome and also biomarkers such as CysC and KIM-1 would help in distinguishing the renal tubular injury and predicting the long-term outcome. Hence, we aimed to assess whether sequential measurements of KIM-1, creatinine, and CysC in pretransplant and immediate post-Tx period could be used as an early biomarker in predicting the long-term outcome, AR episodes and also in detecting the renal tubular and epithelial cell injury when the morphological changes are minimal. In the present study, we enrolled 68 subjects between 2011 and 2012 and followed up them for 5 years.
suBjects and Methods
This prospective study was approved by the ethical committee. Obtained written informed consent from 25 renal transplant patients who received live related/unrelated donor kidney transplantation, 18 patients with CAD (characterized by renal function decline, elevated SCr and proteinuria), and 25 healthy controls (HC) during March 2011-January 2012. Clinical data collected included warm ischemia, cold ischemia time, episodes of ARs, and infections. Transplant patient group were recipients of renal transplant whose samples were collected from baseline to 4-year-post-Tx at regular intervals.
Compliance with ethical standards
The study protocol was approved by the Institute's Ethical Committee, written informed consent was obtained from all patients and study was conducted in compliance with the provisions of the Declaration of Helsinki and good clinical practice guidelines.
Urinary KIM-1 estimation -urine samples were collected before the operation, 12, 24 h, postoperative day (POD) 7, 15, and 6 th month and at the time of discharge after transplantation. KIM-1 was measured quantitatively by sandwich ELISA (R and D Systems) according to the manufacturer's instructions. Samples were centrifuged, aliquoted, and stored at −80°C until processed. Serum CysC was measured using latex-enhanced immune turbid metric method (Dialab GmbH). Intensity of the turbidity was measured and calculated with multicalibrate graph.
Creatinine levels were measured using modified Jaffe reaction of fixed interval. Creatinine clearance (CrCl) was calculated from 24-h urinary creatinine excretion and serum creatinine. Estimated GFR was calculated with the modification of diet in renal disease formula. Creatinine reduction ratio was defined by the difference between baseline and the 7 th day -SCr divided by baselines Cr.
Immunosuppression regimens
All patients were on a triple-drug regime containing a calcineurin inhibitor (CNI) (either tacrolimus [TAC] or cyclosporine [CsA]/along with mycophenolate mofetil [MMF] and prednisolone. MMF 1000 mg twice daily and adjusted according to tolerability, TAC 6-8 mg/day adjusted accordingly based on the trough levels. The target TAC trough level was (10-12 ng/mL) ng/mL for the first 6 months and ≤5 ng/mL thereafter. For CsA, C 0 was 200-300 ng/mL till month 3 and 150-250 ng/mL thereafter. Prednisolone was tapered to 5 mg/day. All the recipients received oral valganciclovir for 3 months and cotrimoxazole for 6 months post-Tx ation.
Follow-up evaluation
At each visit, patient and graft survival status; vital signs; hematology and biochemical parameters, dosage and levels of immunosuppressive agents were estimated. Findings of renal biopsies; and occurrence of rejection, infection, hospitalization, and other significant events were noted. Blood levels of Tac, CsA, and everolimus were measured by chemiluminescent microparticle immunoassay and liquid chromatography-mass spectrometry. All other variables were assessed by standard laboratory methodologies. Patients were followed up weekly for 1 st month, fortnightly for the next 2 months, monthly for 6 months, and thereafter once in 6 months/1 year throughout the study period. All unexplained episodes of graft dysfunction were investigated by biopsy. AR was treated as per standard protocol.
Statistical analysis
For group comparison, Student's t-test was used if data was normally distributed. For analyzing related variables within group, paired t-test was used by two-tailed test wherein P < 0.05 was considered statistically significant. Nonparametric Spearman's correlations were used to determine the relationships concentration of KIM-1 was significantly elevated and remained high in one patient. Two patients had CNI toxicity and were treated accordingly by dosage adjustment where CysC levels were altered.
The diagnostic accuracy of discharge levels of CysC, KIM-1, and SCr for predicting graft function at 4 years which was assessed by ROC curve and calculated by area under curve. CysC emerged as a better marker with an area under the curve (AUC) of 0.841 with 95% confidence interval (CI) of 0.906 with P ≤ 0.001 as depicted in Figure 4a . When we performed ROC in patients with AR KIM1 appeared as a better marker with an AUC of 0.938 with 95% CI of 1.0 and a P = 0.015 [ Figure 4b ].
When we performed Tukey's multiple comparison correlation studies [ Table 2 ] of discharge creatinine levels, CysC levels and KIM-1 levels with 6 months CrCl only discharge CysC showed statistical significance with P = 0.01. Discharge levels of KIM-1 correlated with discharge SCr while discharge CysC correlated with discharge CrCl and 4 th year CrCl. KIM1 levels elevated in rejection patients while CysC changed in response to the changes in GFR induced by either AR or CNI toxicity/infections. In CAD, both KIM-1 and CysC elevated.
discussion
In the present study, we evaluated the ability of CysC and KIM1 as biomarkers of renal function, renal tubular and cellular injury in pre-and post-transplant subjects and in CAD patients. We observed that both CysC and KIM-1 did not show correlation with age, gender, and body mass index of patient. Both KIM-1 and CysC levels elevated after transplantation CysC peaked at 12 h post-Tx whereas KIM-1 peaked at 24 h post-Tx. In uncomplicated and complicated post-Tx, clinical courses CysC correlated well with CrCl than KIM-1 and SCr showing it as a better marker of glomerular function. It is evident that there is a leak back of creatinine into the circulation through the damaged proximal tubules whenever there is low GFR consequently underestimating GFR. [13] It was also observed that there was a fall in the levels of CysC between parameters. For multiple comparisons, Tukey's test was performed. Receiver operating characteristic (ROC) curve analysis to predict positive and negative predictive values was performed using SPSS version 18 software program IBM company, Chicago and Prism Graph Pad 5.
rEsults
Demographic characteristics age, gender, original disease, time on dialysis before transplant, human leukocyte antigen matching, and donor source are presented in [ Table 1 ]. Biopsy-proven ARs were observed in two patients, and CNI toxicity was observed in two patients. Pretransplant values of CysC and KIM-1 were significantly high when compared to that of HC [ Figures 1 and 2 ]. Mean CysC concentration at baseline was (6.41 ± 2.8 mg/L), at 12 h -(7.8 ± 3.2 mg/L), at 24 h -(4.4 ± 2.6 mg/L), at 7 th POD-(3.4 ± 1.7 mg/L), at 15 th POD-(2.8 ± 1.8 mg/L), at 6 m-(1.5 ± 0.7 mg/L) in CAD-(4.4 ± 2.0 mg/L), and in HC (0.65 ± 0.38 mg/L). KIM-1 levels were -at baseline (4.7 ± 2.1 ng/mL), at 12 h (2.5 ± 2.4 ng/mL), at 24 h (6.9 ± 3.2 ng/mL), at 7 th POD-(2.0 ± 2.8 ng/mL), at 15 th POD (2.35 ± 2.6 ng/mL), 6 m (1.04 ± 1.4 ng/mL), in CAD-(1.9 ± 1.6 ng/mL), and in HC (0.41 ± 0.3 ng/mL). Concentrations of CysC increased soon after transplantation and reached to peak (P ≤ 0.001) at 12 h posttransplantation and remained higher than the control up until day 15 of post-Tx. There is a significant increase of these levels observed in the CAD patients also. Urinary KIM-1 levels increased after transplantation and reached peak at 24 h (P ≤ 0.001) post-Tx and remained elevated up until day 15 of post-Tx as compared with HC. In 16 patients with uncomplicated post-Tx course, there was a drastic fall of both CysC and KIM-1 levels. Five patients had postoperative complications which did not interfere with the graft function where there was a change in the concentration of both CysC and KIM-1 and without statistical significance. Two patients had biopsy-proven AR [Figures 3a and b] , reversed with the antirejection therapy. Both CysC and KIM-1 levels increased before the occurrence of the biopsy-proven AR; however, in three patients despite rise in the creatinine levels with the alteration in the urine output, which would help the clinician to reverse adverse insults beforehand.
When we compared the levels of CysC, KIM-1 and S.Cr levels at the time of discharge with that of CrCl at the time of discharge and 4 years posttransplantation only CysC was significantly correlated with CrCl at both the time points. Both KIM-1 and SCr were just above the upper range (2.4 ng/mL and1.75 mg/dL) of the normal whereas CysC (3.3 mg/L) was almost 3-fold above the upper range of the normal range correlating well with the discharge CrCl (45.3 mL/mt). The elevated levels of CysC may reflect proximal tubular injury. [14] . All the three parameters CysC, KIM-1, and SCr levels fell to the baseline in 16 patients with uncomplicated post-Tx course. However, CysC seems to adjust rapidly than the other two in response to changes in GFR. Two patients with biopsy-proven CNI toxicity, it has been noticed that both CysC and KIM-1 levels were on rise, but CysC levels were more prominent reflecting that both may provide an earlier indication of renal damage.
Concentrations of CysC and KIM-1were increased before the occurrence of biopsy-proven AR. Cytatin C concentration decreased with the antirejection treatment whereas it took a while for KIM-1 concentrations to come down owing to the tubular injury. Patient survival was 92% at the end of 4 th year and it was interesting note that the CysC levels at the time of discharge of these two patients were high (>7 mg/L) while SCr and KIM-1 levels were normal.
In CAD patients, all the three parameters increased. Both KIM-1 and CysC did not perform well in predicting CAD.
Earlier studies noticed a correlation between CycC and GFR in renal transplantation [15, 16] but none has established either prognostic value or the long-term outcome. This study is novel by determining the role of these two biomarkers in terms of predicting rejection episodes as well a long-term outcome. The possible limitation of the study is that of smaller sample size. However, preliminary findings were encouraging and warrants for the study in larger cohort.
conclusion
Noninvasive measurements of urinary tubular biomarkers can provide information of the microenvironment of the allograft in transplant recipients. Monitoring their response to host immune system may reveal early state of injury and thus allow the clinician to provide timely intervention. Future advancements in modulating the expression of these biomarkers on tubular cells may also potentially aid in identifying new therapeutic targets.
In summary, both KIM-1 and CysC are useful markers for predicting AR, renal function, and graft survival. Elevated urinary levels of KIM-1 independently predict AR, while CysC is a valuable marker of GFR and a useful tool in predicting graft survival in renal transplant recipients. Further studies with large sample size are required to clarify the specific roles. 25 23 **Correlation is significant at the 0.01 level (two-tailed), *Correlation is significant at the 0.05 level (two-tailed). Cr: Creatinine, CysC: CystatinC, KIM: Kidney injury molecule, CrCl: Creatinine clearance
